Pseudodementia is cognitive impairment from severe depression that mimics primary dementia — and reverses with depression treatment. The term is somewhat misleading (the cognitive impairment is real, not pseudo) but the concept matters clinically. Depression in older adults often presents primarily as cognitive complaints rather than as classic mood symptoms.
Why depression causes cognitive impairment: depression impairs working memory, processing speed, attention, and motivation — producing measurable cognitive deficits on testing. Combined with hippocampal volume loss from chronic stress, anhedonia limiting cognitive engagement, sleep disruption affecting consolidation, and motivation deficits limiting task performance, the cognitive picture can closely mimic early dementia.
Features that suggest pseudodementia over true dementia:
"I don't know" responses rather than confabulation. Depressed patients often answer "I don't know" to test questions without trying; demented patients more often guess or confabulate.
Preserved learning with effort. When pushed, depressed patients can encode and retrieve. Demented patients cannot, regardless of effort.
Prominent mood symptoms and vegetative signs. Depression has a distinct affective and neurovegetative profile.
More rapid onset. Depression often emerges over weeks to months; dementia over months to years.
Patient distress about cognitive impairment. Depressed patients often complain about and worry about their cognitive impairment. Demented patients often have variable insight, sometimes denying problems family clearly observes.
Better performance with cueing. In testing, depressed patients improve with recognition cues; demented patients do not (because they didn't encode).
The clinical approach: any cognitive complaint in an older adult deserves depression screening. PHQ-9, Geriatric Depression Scale (GDS), structured clinical interview. If depression is present, treat it. Reassess cognition after 3-6 months of adequate antidepressant treatment.
Treatment of suspected pseudodementia: start an SSRI (sertraline, escitalopram, citalopram are well-tolerated in older adults). Avoid tricyclics (anticholinergic burden) and high-dose paroxetine (anticholinergic, also pronounced withdrawal). Avoid benzodiazepines (worsen cognition). Adequate dosing and adequate duration (8-12 weeks at therapeutic dose) before declaring treatment failure.
If cognition recovers with depression treatment: pseudodementia confirmed. The patient's "dementia" was depression-driven.
If cognition does not recover despite mood improvement: pursue formal dementia workup (neuropsychological testing, MRI, possibly biomarkers). Many patients have both depression and underlying dementia — depression treatment may improve some symptoms while underlying pathology persists.
Predictive significance: patients who present with apparent pseudodementia have elevated risk of developing dementia over subsequent years, even when their depression treats successfully. The depression may have been an early prodromal sign. Continued cognitive monitoring after depression treatment is appropriate.
When you encounter an older patient with cognitive complaints, depression screening comes first. Treat depression, then reassess cognition. The pseudodementia framework prevents misdiagnosis and ensures patients receive treatable interventions before being labeled with progressive disease.